Not all people with CLL need therapy. Inspite of all the latest innovations, the iwCLL nonetheless endorses watchful observation for individuals with asymptomatic disease.86 This advice is based on at the least two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR). Anda pasti harus https://ronp887jyn2.daneblogger.com/profile